Characteristics of included studies.
| Study, Yr | Treatment | Outcome Measurement Time, wks | Biologic-experienced Patients, % | Group Size | Age, Mean | Female, % | HAQ-DI, Mean (SD) | DAS28, Mean (SD) | PASI, Mean (SD) | Patients Employed, % |
|---|---|---|---|---|---|---|---|---|---|---|
| Kavanaugh, et al, 200610 | PBO | 14 | 0 | 100 | 47 | 49 | 1.1 (0.6) | NR | 10.2 (9.0) | 66.7 |
| IFX, 5 mg/kg | 14 | 0 | 100 | 46.5 | 29 | 1.1 (0.6) | NR | 11.4 (12.7) | 73 | |
| Kavanaugh, et al, 200911 | PBO | 24 | 0 | 113 | 47 | 39 | 1 (0.5) | 4.85 (1.02) | 8.4 (7.4) | NR |
| GOL, 50 mg | 24 | 0 | 146 | 45.7 | 39 | 1 (0.6) | 4.96 (1.10) | 9.8 (8.6) | NR | |
| GOL, 100 mg | 24 | 0 | 146 | 48.2 | 41 | 1.1 (0.6) | 4.89 (1.06) | 11.1 (9.5) | NR | |
| Kavanaugh, et al, 201212 | PBO | 24 | 0 | 206 | 47.4 | 47.6 | 1.3 (0.74) | 5.2 (4.4–6.0)* | 8.8 (7.3) | NR |
| UST, 45 mg | 24 | 0 | 205 | 47.1 | 48.3 | 1.3 (0.74) | 5.2 (4.6–5.7)* | 7.1 (8.9) | NR | |
| UST, 90 mg | 24 | 0 | 204 | 46.8 | 43.1 | 1.3 (0.59) | 5.2 (4.6–5.8)* | 8.4 (7.3) | NR | |
| Kavanaugh, et al, 201513 | PBO | 24 | 19.1 | 136 | 47.3 | 58.1 | 1.3 (0.7) | NR | 7.1 | 56.6 |
| CZP, 200 mg | 24 | 22.5 | 138 | 48.2 | 53.6 | 1.3 (0.7) | NR | 7 | 60.1 | |
| CZP, 400 mg | 24 | 17 | 135 | 47.1 | 54.1 | 1.3 (0.6) | NR | 8.1 | 61.5 | |
| Zhang, et al, 201414 | PBO | 16 | 24.4 | 168 | 51.1 | 47.6 | 1.2 (0.6) | 4.9 (1.0) | 9.1 (9.5) | NR |
| APR, 20 mg | 16 | 22 | 168 | 48.7 | 49.4 | 1.2 (0.6) | 4.8 (1.1) | 7.4 (8.7) | NR | |
| APR, 30 mg | 16 | 24.4 | 168 | 51.4 | 54.7 | 1.2 (0.6) | 4.9 (1.0) | 9.2 (9.7) | NR |
↵* Median (IQR). IFX: infliximab; PBO: placebo; GOL: golimumab; UST: ustekinumab; CZP: certolizumab pegol; APR: apremilast; HAQ-DI: Health Assessment Questionnaire–Disability Index; DAS28: 28-joint Disease Activity Score; PASI: Psoriasis Area Severity Index; IQR: interquartile range; NR: not reported.